BA
The Boeing Company
BA has a slight edge over PSIX overall, supported by stronger fundamentals and lower modeled downside.
PSIX
Power Solutions International, Inc.
PSIX offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
BA Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Stable | |
| Under pressure |
BA's profitability is currently healthy, and its revenue and cash flow are stable, but its balance sheet is under pressure.
PSIX Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Stable | |
| Strong | |
| Strong |
PSIX's cash flow and balance sheet are currently strong, and its profitability is stable, but its revenue is under pressure.
BA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 18x | $172 | — |
| Cheap | 51x | $496 | +189% |
| Fair | 82x | $790 | +360% |
| Expensive | 91x | $876 | +411% |
Historical ranges are pointers, not guarantees.
BA has the edge over PSIX in the historical PE scenario, which offers more potential upside but is not a forecast.
PSIX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 3.1x | $9.56 | -76% |
| Fair | 10x | $31.91 | -19% |
| Forward | 11x | $39.42 | — |
| Current | 13x | $39.42 | — |
| Expensive | 17x | $52.04 | +32% |
Historical ranges are pointers, not guarantees.
PSIX's PE is in its expensive range at 13x. If earnings grow as analysts expect, today's price would be 11x next year's earnings, in its fair range.
BA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Growth | |
| Improving | |
| Limited | |
| Low |
Analysts expect BA to return to profit, with revenue growing. However, they disagree widely on these estimates.
PSIX Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for PSIX, with profitability improving.
BA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $9.66 | +$23.38 |
| Q2 2026 | $2.78 | +$19.33 |
| Q1 2026 | $2.53 | +$20.49 |
| Q4 2025 | $2.48 | +$20.84 |
| Q3 2025 | -$13.72 | -$0.83 |
| Q2 2025 | -$16.55 | -$10.93 |
| Q1 2025 | -$17.96 | -$14.42 |
| Q4 2024 | -$18.36 | -$14.69 |
BA has returned to profit: it earned $9.66 per share over the past year, after losing money the year before.
PSIX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.54 | +16% |
| Q3 2026 | $3.04 | -42% |
| Q2 2026 | $2.94 | -39% |
| Q1 2026 | $4.43 | +25% |
| Q4 2025 | $4.94 | +64% |
| Q3 2025 | $5.26 | +122% |
| Q2 2025 | $4.81 | +145% |
| Q1 2025 | $3.53 | +172% |
| Q4 2024 | $3.01 | +162% |
PSIX has the edge over BA on earnings, with more consistent year-over-year improvement.
BA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.2B | +3.9% |
| Q2 2026 | $24.6B | +8% |
| Q1 2026 | $22.2B | +14% |
| Q4 2025 | $23.9B | +57% |
| Q3 2025 | $23.3B | +30% |
| Q2 2025 | $22.7B | +35% |
| Q1 2025 | $19.5B | +18% |
| Q4 2024 | $15.2B | -31% |
BA's revenue has grown year over year for seven quarters in a row: $24.2B last quarter, up 3.9% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 1.5% | +22 points |
| Q2 2026 | 0.6% | +1.4 points |
| Q1 2026 | 2% | -0.3 points |
| Q4 2025 | 37% | +61 points |
| Q3 2025 | -21% | +12 points |
| Q2 2025 | -0.8% | +5.7 points |
| Q1 2025 | 2.4% | +2.9 points |
| Q4 2024 | -25% | -26 points |
BA's operating margin was 1.5% last quarter, up 22 points from the same quarter a year ago.
PSIX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $202.1M | -0.9% |
| Q2 2026 | $152.5M | -21% |
| Q1 2026 | $128.6M | -5.1% |
| Q4 2025 | $191.2M | +33% |
| Q3 2025 | $203.8M | +62% |
| Q2 2025 | $191.9M | +74% |
| Q1 2025 | $135.4M | +42% |
| Q4 2024 | $144.3M | +38% |
PSIX's revenue has held roughly level: $202M last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 20% | +6.3 points |
| Q2 2026 | 16% | -1.3 points |
| Q1 2026 | 8.9% | -9.3 points |
| Q4 2025 | 13% | -4.8 points |
| Q3 2025 | 14% | -2.3 points |
| Q2 2025 | 17% | -6 points |
| Q1 2025 | 18% | +7 points |
| Q4 2024 | 17% | +5.7 points |
PSIX has the edge over BA on profitability, with a higher operating margin.
BA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $464M | +95% |
| Q2 2026 | $631M | +$831M |
| Q1 2026 | -$1.5B | +$836M |
| Q4 2025 | $375M | +$4.5B |
| Q3 2025 | $238M | +$2.2B |
| Q2 2025 | -$200M | +$4.1B |
| Q1 2025 | -$2.3B | +$1.6B |
| Q4 2024 | -$4.1B | -239% |
BA has the edge over PSIX on cash flow, with more consistent year-over-year improvement.
PSIX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $38.3M | +2119% |
| Q2 2026 | $55.7M | +281% |
| Q1 2026 | $17.2M | +219% |
| Q4 2025 | -$7.6M | -125% |
| Q3 2025 | $1.7M | -86% |
| Q2 2025 | $14.6M | +1679% |
| Q1 2025 | $5.4M | -63% |
| Q4 2024 | $30M | +398% |
PSIX generated $104M in free cash flow over the past year, up 100% from the year before.
BA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +2.1M shares |
| 1 year | +4.3% | +32.8M shares |
| 3 years | +31% | +186M shares |
| 5 years | +35% | +204M shares |
| Available history | +40% | +227M shares |
BA has 793M diluted shares, up 4.3% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2019 | — |
PSIX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +3K shares |
| 1 year | +0.1% | +14K shares |
| 3 years | +0.4% | +101K shares |
| 5 years | +0.7% | +155K shares |
| Available history | +7.2% | +1.5M shares |
PSIX has the edge over BA on shareholder dilution, with a more favorable share count trend.
BA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 3.0x | Elevated |
| Q2 2026 | 5.7x | High |
| Q1 2026 | 6.0x | High |
| Q4 2025 | 6.9x | High |
| Q2 2024 | 361.8x | High |
| Q1 2024 | 36.1x | High |
| Q4 2023 | 36.4x | High |
| Q3 2023 | 96.1x | High |
BA's net debt is about 3.0 years of its operating earnings (EBITDA), down from more than 20 years a year ago.
PSIX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.7x | Net Cash |
| Q2 2026 | -0.7x | Net Cash |
| Q1 2026 | -0.4x | Net Cash |
| Q4 2025 | -0.4x | Net Cash |
| Q3 2025 | -0.4x | Net Cash |
| Q2 2025 | 0.4x | Very low |
| Q1 2025 | 0.6x | Very low |
| Q4 2024 | 0.8x | Very low |
PSIX has the edge over BA on leverage, with a lower net debt burden relative to earnings.
BA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 31.1 | Neutral |
| Stochastic | 9.6 | Oversold |
BA's weekly RSI is 31 (neutral) and its Stochastic is 10 (oversold).
PSIX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.7 | Neutral |
| Stochastic | 49.7 | Neutral |
PSIX's weekly RSI is 44 (neutral) and its Stochastic is 50 (neutral).
BA PE vs Industrials Sector
| Metric | BA | Sector median | Relative |
|---|---|---|---|
| PE | 18x | 24x | 26% below |
| PE % | 0 | 58 | 58 pts below |
BA is trading at 18x earnings, a 26% discount to the Industrials sector's median of 24x, though its earnings don't support one.
PSIX PE vs Industrials Sector
| Metric | PSIX | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 24x | 46% below |
| PE % | 66 | 58 | 8 pts above |
PSIX has the edge over BA on valuation relative to its sector.
BA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $184.6 | 7.1% below |
| 20 week MA | $203.8 | 16% below |
| 50 week MA | $215.5 | 20% below |
| 100 week MA | $205.9 | 17% below |
| 200 week MA | $200.6 | 14% below |
BA is in a downtrend: it's below all five of its weekly moving averages, and 14% below its 200-week average.
PSIX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $44.7 | 12% below |
| 20 week MA | $40.0 | 1.4% below |
| 50 week MA | $54.1 | 27% below |
| 100 week MA | $55.3 | 29% below |
| 200 week MA | $31.2 | 27% above |
PSIX has the edge over BA on trend strength, trading above more of its moving averages.
BA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $330.1 | $217.2 | -34% |
| 2021 | $217.2 | $204.2 | -6% |
| 2022 | $204.2 | $189.1 | -7.4% |
| 2023 | $189.1 | $260.7 | +38% |
| 2024 | $260.7 | $180.7 | -31% |
| 2025 | $180.7 | $216.4 | +20% |
| 2026 YTD | $216.4 | $171.6 | -21% |
BA has the edge over PSIX on returns for 2026, with the stronger performance.
PSIX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $4.25 | $3.26 | -23% |
| 2021 | $3.26 | $2.95 | -9.5% |
| 2022 | $2.95 | $2.92 | -1% |
| 2023 | $2.92 | $2.05 | -30% |
| 2024 | $2.05 | $27.1 | +1220% |
| 2025 | $27.1 | $65.5 | +142% |
| 2026 YTD | $65.5 | $39.4 | -40% |
PSIX has finished lower in four of the last six years. It's down 40% so far in 2026.